Characterization of the Doxorubicin-Pluronic F68 Conjugate Micelles and Their Effect on Doxorubicin Resistant Human Erythroleukemic Cancer Cells
- *Corresponding Author:
- Ying-Zheng Zhao
Present address: Pharmacy School
Wenzhou Medical College
Zhejiang Province 325035, China
E-mail: [email protected]
Received Date: August 24, 2011; Accepted Date: September 30, 2011; Published Date: October 03, 2011
Citation: Sun CZ, Lu CT, Zhao YZ, Guo P, Tian JL, et al. (2011) Characterization of the Doxorubicin-Pluronic F68 Conjugate Micelles and Their Effect on Doxorubicin Resistant Human Erythroleukemic Cancer Cells. J Nanomedic Nanotechnol 2:114. doi:10.4172/2157-7439.1000114
Copyright: © 2011 Sun CZ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Doxorubicin-pluronic F68 conjugate (DOX-P) was synthesized and its structure was confirmed by FTIR and 1H-NMR spectra. Using human erythroleukemic cancer cells as model, DOX-P application in chemotherapy was further investigated. Differential scanning calorimetry analysis was applied to compare the fusion and crystallization characterization between pluronic F68 and DOX-P. Morphology and size assessment were measured using a transmission electron microscopy (TEM) to confirm the capability of forming micelles of DOX-P. Tumor cell lines K562 and K562/AO2 were used to investigate the effect of DOX-P on tumor cell resistance. The Tm and Tc of DOX-P were lower than pluronic F68 resulted from the connection of DOX to pluronic F68. Morphology images confirmed the existence of DOX-P micelles, with an average size of about 20 nm. Drug release profile showed that the DOX-P conjugate maintained a sustained DOX release. From cell experiment in vitro, DOX-P micelles could circumvent the DOX resistance of K562/AO2 cells. With advantages of EPR effect and reducing tumor resistance, DOX-P micelles might develop as new tumor targeted delivery system for chemotherapy.